Czechia vs Libya: HIV/AIDS deaths averted by antiretroviral therapy
Czechia
150 deaths
in 2022
Libya
164.5 deaths
in 2024
Czechia rank
117th
Libya rank
114th
HIV/AIDS deaths averted by antiretroviral therapy over time
- Czechia
- Libya
How they compare
Libya currently reports 164.5 deaths against 150 deaths in Czechia, a difference of 14.5 deaths.
That makes Libya's figure about 1.1 times Czechia's.
The two have swapped places 2 times across 33 shared years of data; in 1990 it was Libya ahead.
Czechia ranks 117th and Libya ranks 114th of 157 countries.
Across the 4 decades both report, Czechia averaged higher in 1 and Libya in 3.
Head to head by decade
| Decade | Czechia | Libya | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 3.9 deaths | 0 deaths | 3.9 deaths | Czechia |
| 2000s | 41.6 deaths | 58.07 deaths | 16.47 deaths | Libya |
| 2010s | 104.7 deaths | 191.14 deaths | 86.44 deaths | Libya |
| 2020s | 148 deaths | 192.67 deaths | 44.67 deaths | Libya |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, Czechia or Libya?
- Libya, at 164.5 deaths against 150 deaths in Czechia as of 2024.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between Czechia and Libya?
- 14.5 deaths, with Libya ahead.
- How many years of comparable data are there for Czechia and Libya?
- 33 years are reported by both, from 1990 to 2022.
- How do Czechia and Libya rank globally for hiv/aids deaths averted by antiretroviral therapy?
- Czechia ranks 117th and Libya ranks 114th of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.